Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Hyperlipidemia Market Growth Evolved From 2024 To 2025, And What’s Ahead?
In recent times, the hyperlipidemia market has displayed consistent growth. It is projected to expand from a valuation of $20.24 billion in 2024 to $20.92 billion in 2025, indicating a Compound Annual Growth Rate (CAGR) of 3.4%. The growth witnessed in the previous years is due to factors such as an increased need for effective treatments, geographical outreach, enhanced public consciousness about hyperlipidemia, and tobacco consumption.
The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $24.24 billion in 2029 at a compound annual growth rate (CAGR) of 3.8%. The growth in the forecast period can be attributed to growing demand for hyperlipidemia drugs, global health initiatives, aging population, preventive care and early intervention. Major trends in the forecast period include novel therapies, digital health technologies in hyperlipidemia management, biomarkers in hyperlipidemia diagnosis and treatment, research & development activities of pharmaceuticals treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp
What are the Fundamental Drivers and Innovations Shaping the Hyperlipidemia Market?
The hyperlipidemia market is predicted to expand, stimulated by an escalating number of chronic illnesses like heart disease. Heart diseases comprise conditions that impact the heart and its operations. Hyperlipidemia treatments assist individuals afflicted with heart disease by lessening the likelihood of heart attacks, preventing strokes, enhancing endothelial function, and lessening the necessity for invasive procedures. For instance, data from the British Heart Foundation, a cardiovascular research charity located in the UK, revealed that around 7.6 million individuals in the UK suffer from heart and circulatory disorders in September 2024; this includes approximatively 4 million males and 3.6 million females with these conditions. These ailments account for approximately 27% of all UK deaths, amounting to over 170,000 deaths per year or approximately 480 deaths daily, which equates to one death every three minutes. As such, the rising occurrences of chronic conditions like heart disease are driving the hyperlipidemia market’s expansion.
How Is the Hyperlipidemia Market Segmented?
The hyperlipidemiamarket covered in this report is segmented –
1) By Type: Familial; Acquired
2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatment
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH); Familial Combined Hyperlipidemia; Familial Dysbetalipoproteinemia
2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia; Secondary Hyperlipidemia; Drug-Induced Hyperlipidemia
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=12873&type=smp
Which Regions Are Driving the Next Phase of the Hyperlipidemia Market Growth?
North America was the largest region in the hyperlipidemia market in 2024. The regions covered in hyperlipidemia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Hyperlipidemia Market?
Key players in the hyperlipidemia market are strategically working on innovative product development with an emphasis on cutting-edge low-density lipoprotein cholesterol-reducing treatments to maintain a competitive edge. Take for instance, in March 2024, Regeneron Pharmaceuticals, Inc., a biotechnology firm in the US, obtained approval from the U.S. Food & Drug Administration (FDA) for the Praluent (alirocumab) Injection. This marks a substantial progress in the treatment of heterozygous familial hypercholesterolemia (HeFH) for children aged 8 and above by providing a focused way to control perilously high levels of low-density lipoprotein cholesterol (LDL-C). The recent green light from FDA is backed by results from a phase 3 trial that demonstrated a 31% decrease in LDL-C levels with regular dosage. The drug’s proven safety record, mirroring that of adults, gives parents and healthcare professionals reassurance, and its distinction as the inaugural therapy tackling the genetically-verified PCSK9 protein sets an important precedent in heart disease therapy. Collectively, these qualities make Praluent an important tool in tackling high cholesterol in HeFH-affected children.
View the full report here:
https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report
How Is the Hyperlipidemia Market Defined and What Are Its Core Parameters?
Hyperlipidemia is a medical condition characterized by abnormally high levels of lipids (fats) in the blood, including cholesterol and triglycerides. It is a common metabolic disorder and a significant risk factor for cardiovascular diseases.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12873
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model